
    
      In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to
      receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk
      test was performed at baseline and repeated after 6 months and the values were compared.
    
  